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Abstract
Background: An imbalance in the production of proinflammatory and anti-inflammatory cytokines may play a role
in the pathophysiology of perimenopausal depression. The aim of this study was to examine serum levels of the
proinflammatory cytokines interleukin 6 (IL-6) and tumor necrosis factor a (TNFa), and the anti-inflammatory
cytokine IL-10, in perimenopausal women suffering from depression. Furthermore, to assess whether serum
cytokine levels are associated with the presence of hot flashes or the use of selective serotonin reuptake inhibitors
(SSRIs). We also evaluated the possible association of hot flashes and perimenopausal depression.
Methods: Serum samples from 65 perimenopausal women, 41 with depression and 24 without depression, were
assessed for serum IL-6, TNFa and IL-10 by conventional enzyme-linked immunosorbent assays. Depression was
evaluated by the 17-item Hamilton Depression Rating Scale (HAM-D 17) and a psychiatric interview. The presence
and severity of hot flashes were examined using the Menopause Rating Scale (MRS).
Results: Serum levels cytokines did not differ between depressed women and normal controls. Serum levels of
cytokines did not change significantly in depressed women with hot flashes or in depressed women treated with
SSRIs. Hot flashes were strongly associated (P < 0.0001) with perimenopausal depression.
Conclusion: The study supports the hypothesis that perimenopausal depression is not characterized by increased
proinflammatory cytokines and decreased anti-inflammatory cytokines. Women with perimenopausal depression
suffer from more severe and more frequent hot flashes than women without perimenopausal depression.
Keywords: antidepressants, cytokines, depression, hot flashes, interleukin 6 (IL-6), interleukin 10 (IL-10), perimeno-
pause, tumor necrosis factor a?α? (TNFa?α?)
Introduction
Throughout most of their lives, women are at greater
risk of becoming depressed than men. The perimeno-
pause and early postmenopausal period has been consid-
ered as ‘window of vulnerability’, during which emerging
physical and emotional discomforts and hormonal
changes can lead to the appearance of depression [1-3].
The mechanisms responsible for the development of
depression in perimenopausal women remain unclear.
Major depression, in general, is associated with
inflammatory processes and neural-immune interactions
[4-9]. Proinflammatory cytokines, such as interleukin 6
(IL-6) and tumor necrosis factor a (TNFa) have been
considered as key neuromodulators of behavioral, neu-
roendocrine and neurochemical features of depressive
disorders [10]. This view is supported by the frequent
appearance of depressive features in cytokine-mediated
chronic inflammatory responses, such as rheumatoid
arthritis, and in cytokine-treated patients with cancer
and chronic hepatitis C [11]. Administration of proin-
flammatory cytokines in animals induces ‘sickness beha-
vior’, similar to the behavioral symptoms of depression
in humans [8].
Postmenopausal women seem to have higher serum
levels of IL-6 and TNFa compared to women of repro-
ductive age [12]. The extent by which the cytokine
milieu is altered in women with perimenopausal depres-
sion is the focus of ongoing investigation. A single study
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vated plasma IL-6 and soluble IL-6 receptor (sIL-6R)
[13]. The same study failed to find an association
between the levels of these cytokines and the appear-
ance of hot flashes. However, another study showed that
serum IL-8 concentrations in premenopausal, perimeno-
pausal and postmenopausal women and bilateral
oophorectomized women with severe hot flashes were
significantly higher than those in women without hot
flashes [14].
Selective serotonin reuptake inhibitors (SSRIs) are a
first-line treatment for perimenopausal depression, but
hormone therapy could be considered for women
experiencing menopausal symptoms unless there are
contraindications [15].
The aims of this study were to simultaneously mea-
sure the levels of the proinflammatory cytokines IL-6
and TNFa and the anti-inflammatory cytokine IL-10 in
women with or without perimenopausal depression, and
to assess whether cytokine levels are associated with hot
flashes or with the use of selective serotonin reuptake
inhibitors. We also examined whether the presence and
severity of hot flashes contribute to the presence of peri-
menopausal depression.
Methods
Subjects
A total of 65 women were recruited consecutively as a
case series from the Outpatient Clinics and the Depart-
ments of Obstetrics & Gynecology and Psychiatry of the
University Hospital of Larissa, Greece participated in the
study. All participants were Caucasians. Participants
were divided into two groups. The first group consisted
of perimenopausal women suffering from depression (n
= 41) and the second consisted of perimenopausal
women without depression (n = 24). All women were in
the perimenopausal phase, defined by the presence of
irregular cycles or amenorrhea for less than 12 months.
The serum levels of follicle-stimulating hormone (FSH)
of each of the participant of the study were more than
40 mIU/ml [16].
Exclusion criteria were: the presence of bipolar disor-
der, other psychiatric diseases (for example, schizophre-
nia), diseases which can affect the immune system or
cause depression (for example, rheumatoid arthritis), the
use of medications except for SSRIs, recent stressful
situations such as bereavement, hysterectomy, oral con-
traceptives and hormone replacement therapy.
Among the 41 women with depression, 19 had a his-
tory of depression and they were taking SSRIs such as
citalopram, fluoxetine or sertraline alone. Each woman
had been taking SSRIs for a period of more than a
month without any other psychotropic or non-psycho-
tropic medication. These women had experienced more
than two episodes of depression in the past and they
were still depressed when enrolled into the study (17-
item Hamilton Depression Rating Scale (HAM-D 17)
score > 10). Consequently, this subgroup of depressed
perimenopausal women treated with SSRIs were classed
as patients resistant to this class of antidepressants and
therefore still depressed. The remaining 22 had their
first episode of depression during perimenopause and
they had never used psychotropic medications. Depres-
sion was diagnosed through a psychiatric interview and
administration of the HAM-D 17. A woman was consid-
ered depressed if she had scored over 10 on the HAM-
D 17 and had fulfilled the criteria of major depression
according to the International Classification of Diseases,
tenth edition (ICD-10). If a woman had scored 10 or
less on the HAM-D 17 she was considered normal. Hot
flashes were examined using the Menopause Rating
Scale (MRS) and they were classified as: absent, mild,
moderate, severe or very severe [17,18].
Venous blood samples were collected between 8.00
AM and 12.00 AM. Samples were centrifuged at 3,500
rpm for 5 minutes and aliquots of serum samples were
stored at -80°C until further use.
Informed consent for participation in this study was
obtained from each woman. The ethics committee of
the University Hospital of Larissa approved the study.
Measurement of serum cytokine concentrations
IL-6, IL-10 and TNFa concentrations were determined
by conventional, commercially available ELISA kits
(Bender Medsystems, Vienna, Austria) in accordance
with the manufacturer’s instructions. Each determina-
tion was performed in duplicate, and average values
were used for statistical analysis. The limits of detection
were 0.92 pg/ml for IL-6, 2.3 pg/ml for TNFa and 0.99
pg/ml for IL-10. The intra-assay coefficients of variation
were 3.4% for IL-6, 6.0% for TNFa and 3.2% for IL-10.
The inter-assay coefficients of variation were 5.2% for
IL-6, 7.4% for TNFa and 5.6% for IL-10.
Statistical analysis
Data analysis was conducted using the commercially
available computer software SPSS V.15.0 (SPSS Inc.,
Chicago, IL, USA). The normality assumption was
checked using the Shapiro test. As departures from nor-
mality were significant, non-parametric methods were
used.
Results are presented as medians (10% to 90%). The
differences in cytokine concentrations between
depressed and non-depressed perimenopausal women
were analyzed with the Mann-Whitney U test. The rela-
tionship between hot flashes and depression was ana-
lyzed with the c
2 test, and the Kruskal-Wallis test was
used in order to detect any association between hot
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A difference between two groups was considered to be
statistically significant when P < 0.05.
Results
The major characteristics of the perimenopausal women
with or without depression are summarized in Table 1.
The two groups did not differ in terms of age, years of
education, months of amenorrhea, smoking habits or
marital status. As was expected, depressed women
scored higher on the HAM-D 17 than women without
depression (Table 1). In many women, the cytokine
levels were below the limits of detection [19]. Table 2
shows the number of cases below sensitivity in the clini-
cal sample and in the control sample, respectively.
Association of serum cytokine concentrations with
perimenopausal depression
The results of serum cytokine concentrations for indivi-
dual cases of perimenopausal women with or without
depression are shown in Table 3. Tables 4 and 5 show
the serum concentrations of the considered cytokines in
the different subgroups of women (Table 4 shows
perimenopausal women with depression not treated and
those treated with SSRIs vs perimenopausal women
without depression; Table 5 shows the total group of 65
perimenopausal women divided into 5 subgroups on the
basis of the severity of hot flashes). The concentration
of cytokines of women with depression did not differ
significantly from those of normal controls (Table 3).
However, it should be noted that for serum levels of
TNFa there is an increasing trend and for levels of IL-6
there is a decreasing trend in the two subgroups of peri-
menopausal women with depression (treated and not
treated with SSRIs) when compared to perimenopausal
women without depression.
Association of serum cytokine concentrations
with hot flashes
The presence and severity of hot flashes were strongly
and positively associated with perimenopausal depres-
sion (c
2 test, P <0 . 0 0 0 1 )( F i g u r e1 ) .T h es a m es t r o n g
positive association was detected between hot flashes
and the HAM-D 17 score (Kruskal-Wallis, P < 0.0001).
Depressed women show more hot flashes of the moder-
ate-to-severe type in contrast to the absent-to-moderate
type of hot flashes in normal controls.
Perimenopausal women were divided into five groups
according to the presence and severity of hot flashes
(Menopause Rating Scale). The first group consisted of
women with no hot flashes, the second women with
mild hot flashes, the third women with moderate hot
flashes, the fourth women with severe and the fifth
women with very severe hot flashes. The levels of cyto-
kines in these five groups are shown in Table 5. The
levels of TNFa (P =0 . 4 9 5 ) ,I L - 6( P =0 . 4 5 6 )a n dI L - 1 0
(P = 0.332) did not show any statistically significant dif-
ferences between groups of perimenopausal women sub-
divided in accordance to the severity of hot flashes.
Similarly, a lack of statistically significant difference
was obtained when analysis was carried out in perime-
nopausal women with depression divided into five
groups according to the presence and severity of hot
flashes in relation to the levels of TNFa (P = 0.583), IL-
6( P =0 . 7 1 9 )a n dI L - 1 0( P = 0.745) in these five groups
(Table 6). Moreover, a comparison of the presence and
severity of hot flashes was made between depressed
women taking SSRIs and depressed perimenopausal
women not taking SSRIs. The result was that SSRIs did
not affect the presence and severity of hot flashes
(Mann-Whitney U, P = 0.710).
Discussion
The main finding of this study in Caucasian patients is
that the proinflammatory cytokines IL-6 and TNFa are
not significantly increased and the anti-inflammatory
cytokine IL-10 is not decreased in perimenopausal
Table 1 Demographic characteristics of women with or
without perimenopausal depression
Characteristic Perimenopausal
women with
depression
(n = 41)
Perimenopausal
women without
depression
(n = 24)
P value
Age 50.10 ± 3.95 48.29 ± 10.95 0.94 (NS)
a
Education,
years
8.22 ± 3.87 8.29 ± 3.93 0.94 (NS)
a
Amenorrhea,
months
6.88 ± 4.62 7.10 ± 3.94 0.59 (NS)
a
Married 36 (87.8%) 22 (91.7%) 0.37 (NS)
b
Current
smokers
15 (36.6%) 7 (29.2%) 0.6 (NS)
b
HAM-D 16.85 ± 5.02 5.68 ± 2.52 < 0.0001
a
aMann-Whitney U test.
bc
2 test.
HAM-D, Hamilton Depression Rating Scale; NS, not significant.
Table 2 Showing the sensitivity threshold for each
cytokine and the number of cases below sensitivity in
the clinical sample and in the control sample,
respectively
Cytokine Sensitivity
threshold
(pg/ml)
Perimenopausal
women with
depression (n = 41);
N = below sensitivity
(true zeros)
Controls (n = 24);
N = below
sensitivity (true
zeros)
TNFa 2.3 28 18
IL-6 0.92 31 18
IL-10 0.99 32 17
IL = interleukin; TNF = tumor necrosis factor.
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strength to the cytokine hypothesis of depression, which
supports the view that depression in general is charac-
terized by increased levels of proinflammatory cytokines,
such as IL-6 and TNFa, and decreased levels of anti-
inflammatory cytokines, such as IL-10. According to this
hypothesis specific alterations of the cytokine environ-
ment are induced by external and internal stressors and
by an increased translocation of lipopolysaccharide
(LPS) from Gram-negative bacteria (leaky gut) [20,21].
The study of Ushiroyama et al.[ 1 3 ]m e a s u r e dI L - 6i na
large sample of non-Caucasian patients. He found
increased plasma levels of IL-6 in the subgroup of
women with depression and hot flashes when compared
to women with hot flashes without depression and to
control subjects. However, it has to be mentioned that
in our study there was a trend in increasing levels for
TNFa and a trend in decreasing levels for IL-6 in peri-
menopausal women with depression when compared to
perimenopausal women without depression. This is in
Table 3 Serum cytokine concentrations in 41 women with perimenopausal depression, compared to those women
without perimenopausal depression (n = 24)
Cytokine Perimenopausal women with
depression (n = 41)
Perimenopausal women without
depression (n = 24)
P value, Mann-Whitney
TNFa 7.07 (1.79 to 18.10) 3.99 (3.01 to 16.50) 0.537, NS
IL-6 1.89 (0.23 to 4.33) 6.23 (0.95 to 22.10) 0.900, NS
IL-10 3.44 (1.08 to 12.00) 3.18 (1.31 to 12.90) 0.726, NS
The results of cytokines are expressed as medians (10% to 90%). Unit of serum cytokine concentration is pg/ml.
IL = interleukin; NS = not significant; TNF = tumor necrosis factor.
Table 4 Serum cytokine concentrations in 41 women with perimenopausal depression, subdivided into those receiving
(n = 19) or not (n = 22) selective serotonin reuptake inhibitors (SSRIs) compared to those women without
perimenopausal depression (n = 24)
Cytokine Perimenopausal women with depression Perimenopausal women
without depression, N = 24
P value, Kruskal-Wallis
Not treated with SSRIs, N = 22 Treated with SSRIs, N = 19
TNFa 9.84 (2.3 to 21.90) 6.31 (4.08 to 9.23) 6.66 (3.01 to 16.50) 0.215, NS
IL-6 1.75 (1.13 to 2.95) 2.47 (1.59 to 4.67) 0.00 (0.00 to 5.63) 0.364, NS
IL-10 5.69 (3.39 to 12.00) 3.91 (1.08 to 10.20) 5.46 (1.31 to 12.90) 0.942, NS
The results of cytokines are expressed as medians (10% to 90%). Unit of serum cytokine concentration is pg/ml.
IL = interleukin; NS = not significant; TNF = tumor necrosis factor.
Table 5 Serum cytokine concentrations in 65 perimenopausal women subdivided into five groups according to the
presence and severity of hot flashes (Menopause Rating Scale)
Cytokine Hot flashes P value, Kruskal-Wallis
Without (n = 8) Mild (n = 16) Moderate (n = 11) Severe (n = 20) Very severe (n = 10)
TNFa 8.67 (3.84 to 13.50) 4.47 (1.84 to 7.35) 5.42 (3.49 to 7.35) 5.82 (4.08 to 9.23) 11.15 (3.01 to 21.90) 0.495, NS
IL-6 22.10 1.19 (0.95 to 1.44) 2.42 (1.13 to 4.31) 3.02 (1.26 to 6.96) 2.11 (1.50 to 2.95) 0.456, NS
IL-10 8.43 (3.97 to 12.90) 1.91 6.57 (2.40 to 12.60) 3.48 (1.08 to 10.20) 5.45 1.31 to 12.00) 0.332, NS
The results of cytokines are expressed as medians (10% to 90%). Unit of serum cytokine concentration is pg/ml.
IL = interleukin; NS = not significant; TNF = tumor necrosis factor.
Figure 1 Perimenopausal women were divided into five groups
according to the presence and severity of hot flashes
(Menopause Rating Scale). The presence and severity of hot
flashes were strongly and positively correlated with perimenopausal
depression (P < 0.0001).
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as far as TNFa, while it is in contrast to what has been
shown for IL-6; it is reported that both cytokines
increase significantly in depressed patients when com-
pared to normal subjects [9,22-24].
Our findings are not unexpected as perimenopause is
associated with spontaneous increases of proinflamma-
tory cytokines, especially IL-6 and TNFa,a t t r i b u t e dt o
decreased levels of estrogens. This release seems to
affect perimenopausal women without distinction
among those with or without depression. The mechan-
ism by which estrogens alter cytokine expression is elu-
sive and may include interactions of the estrogen
receptors with other transcription factors, modulation of
nitric oxide activity, antioxidative effects, plasma mem-
brane actions and changes in immune cell function [25].
According to our findings these cytokine levels are not
statistically different among those with or without
depression. Circulating cytokine levels may not reflect
the local production of cytokines in women with depres-
sion and a better understanding of local cytokine levels
would be more informative. Cerebrospinal fluid levels of
cytokines have been measured in other infectious and
non-infectious diseases, including psychiatric disorders
such as schizophrenia, as an indicator of central nervous
system (CNS) cytokine levels. It is well known that cyto-
kines are synthesized mainly by monocytes, but they can
also be secreted by other immune and non-immune
cells, such as microglia and astrocytes in the CNS [26].
The design of the present study did not allow for inva-
sive procedures, such as collection of cerebrospinal fluid
(CSF) and measurements of cytokine levels in such bio-
logical material.
It also needs to be noted that variations in standards
and pairs of antibodies used by different companies may
affect the validity and the performance of the ELISA kits
used for the measurement. Thus, differences in the sen-
sitivity and specificity of these kits have been reported
[27].
We found a significant association between hot flashes
and perimenopausal depression. Such an association
adds support to the ‘domino theory’ of the pathophysiol-
ogy of perimenopausal depression. This theory asserts
that experience of the somatic symptoms, caused by
diminishing estrogen, is the direct cause of the onset of
depression during perimenopause. Mental and physical
discomforts such as hot flashes, inability to concentrate,
insomnia, and vasomotor symptoms, which characterize
the menopausal transition, may easily disrupt a woman’s
emotional life. In particular, when combined with a lack
of understanding of or control over their source, these
symptoms may lead a woman into a downward spiral
towards depression [3,28-33]. The association of hot
flashes with perimenopausal depression is not a consis-
tent finding, as Ozturk et al. were unable to report it
[34].
When we analyzed our data in relation to the admin-
istration or not of SSRIs, we found that despite their
presumed immunomodulatory properties (in favor of
decreased IL-6) [35,36], SSRIs are not linked to any spe-
cific cytokine. Suppression of proinflammatory cytokines
does not occur in patients who fail to respond to SSRIs
(treatment-resistant depression) [37] and our report
demonstrates that this is also the case in perimenopau-
sal depression. A plausible explanation for this would be
that SSRIs cannot relieve women from severe vasomotor
and other symptoms associated with decreased estrogen,
which cause the perimenopausal depression; conse-
quently, perimenopausal depression becomes refractory
to treatment with antidepressants and proinflammatory
cytokines are not suppressed in depressed perimenopau-
sal women who take SSRIs.
C y t o k i n e ss u c ha sI L - 6a n dT N F a appear to be
increased in menopause and to be potent vasodilators
[38,39]. This raises the question as to whether they
would be further increased in the subgroup that experi-
enced hot flashes. It appears that in our enrolled peri-
menopausal women neither IL-6 and TNFa or IL-10
were associated with the presence or the severity of hot
flashes.
The present study has several limitations. First of all
circulating cytokine levels do not necessarily reflect the
local production of cytokines in women with depression.
Moreover, this study is a preliminary report and its data
should be confirmed by studies that include larger sam-
ples of patients and controls.
Table 6 Serum cytokine concentrations in 41 perimenopausal women with depression subdivided into five groups
according to the presence and severity of hot flashes (Menopause Rating Scale)
Cytokine Hot flashes P value, Kruskal-Wallis
Without, (n = 2) Mild, (n = 7) Moderate, (n = 6) Severe, (n = 17) Very severe, (n = 9)
TNFa 0.00 (true zero) 4.61 (1.84 to 7.35) 7.35 8.99 (4.65 to 14.30) 13.19 (7.12 to 21.90) 0.583, NS
IL-6 0.00 (true zero) 1.44 (1.44 to 1.44) 1.13 2.50 (1.44 to 4.67) 2.11 (1.50 to 2.95) 0.719, NS
IL-10 0.00 (true zero) 0.00 (true zero) 4.54 4.96 (3.10 to 10.20) 6.83 (3.44 to 12.00) 0.745, NS
The results of cytokines are expressed as medians (10% to 90%). Unit of serum cytokine concentration is pg/ml.
IL = interleukin; NS = not significant; TNF = tumor necrosis factor.
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It seems that hot flashes play a crucial role in the pre-
sence of perimenopausal depression. The inflammatory
theory of depression is not suitable for perimenopausal
depression, since serum concentrations of the proin-
flammatory cytokines TNFa and IL-6 are not raised.
Perimenopausal depression has unique characteristics
that must be taken into account during its treatment,
with an emphasis on hormone replacement therapy that
will alleviate the hot flashes and improve the perimeno-
pausal depression prognosis.
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